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IntroductIon
Chronic hepatitis B virus (HBV) infection is a 
major risk factor in the development of hepatocellular 
carcinoma (HCC) in Southeast Asia. Approximately 
90% of HCC is due to HBV infection in the locality. 
Epidemiological studies have shown that the relative 
risk of HCC among HBV carriers is 10-fold higher than 
that of non-carriers [1]. Thus, an understanding of the 
mechanism by which HBV induces HCC formation is 
of great significance. HBV DNA is integrated and often 
highly rearranged within the host DNA in HCC tumors 
[2–3]. These templates frequently produce a 154-amino 
acid HBV viral oncoprotein, HBx, which is active in 
transactivation assays [4]. The sustained production of 
HBx is associated with hepatocellular transformation and 
represents a major contribution of HBV to HCC [5]. We 
and others have reported that HBV integration is detected 
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AbstrAct
Tumor relapse after chemotherapy typifies hepatocellular carcinoma (HCC) and 
is believed to be attributable to residual cancer stem cells (CSCs) that survive initial 
treatment. Chronic infection with hepatitis B virus (HBV) has long been linked to 
the development of HCC. Upon infection, random HBV genome integration can lead 
to truncation of hepatitis B virus X (HBx) protein at the C-terminus. The resulting 
C-terminal-truncated HBx (HBx-∆C) was previously shown to confer enhanced 
invasiveness and diminished apoptotic response in HCC cells. Here, we found HBx-
∆C to promote the appearance of a CD133 liver CSC subset and confer cancer and 
stem cell-like features in HCC. HBx-∆C was exclusively detected in HCC cell lines that 
were raised from patients presented with a HBV background with concomitant CD133 
expression. Stable overexpression of the naturally occurring HBx-∆C mutants, HBx-
∆14 or HBx-∆35, in HCC cells Huh7 and immortalized normal liver cells MIHA resulted 
in a significant increase in the cells ability to self-renew, resist chemotherapy and 
targeted therapy, migrate and induce angiogenesis. MIHA cells with the mutants 
stably overexpressed also resulted in the induction of CD133, mediated through STAT3 
activation. RNA sequencing profiling of MIHA cells with or without HBx-∆C mutants 
stably overexpressed identified altered FXR activation. This, together with rescue 
experiments using a selective FXR inhibitor suggested that C-terminal truncated HBx 
can mediate cancer stemness via FXR activation. Collectively, we find C-terminal 
truncated HBx mutants to confer cancer and stem cell-like features in vitro and to 
play an important role in driving tumor relapse in HCC.
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in 80–90% of host genomes from HBV-infected HCC 
cases and that the HBx gene is often partially deleted 
during the integration process, causing the C-terminal 
truncation of HBx [6–9]. We and others have also found, 
through both in vitro and in vivo studies, that C-terminal 
truncated HBx (HBx-ΔC) plays a critical pro-oncogenic 
and pro-metastatic role in hepatocarcinogenesis [10–13]. 
A recent study by Quetier et al. found that the HBx protein 
with C-terminal deletions was more susceptible to DEN-
induced hepatocarcingoenesis than the full-length HBx 
protein in a mice model, through increased expression of 
IL-6, TNF-α and IL-1β transcripts as well as activation 
of STAT3, ERK and JNK proteins [14]. These results 
demonstrate that, in addition to the full-length HBx, HBx-
ΔC also plays an important, and likely a more critical role, 
in HCC development. 
Recent compelling evidence has emerged in 
support of a cancer stem cell (CSC)/tumor-initiating 
cell (T-IC) model in leukemia and a wide range of solid 
tumors, including HCC. CSCs are believed to harbor both 
cancer cell- and stem cell-like characteristics, including 
uncontrolled growth, self-renewal, differentiation and 
chemoresistance. These cells are now widely regarded 
as the root of tumor origin and recurrence. In HCC, 
specifically, microarray analyses of human HCC samples 
identified the molecular similarities between CSCs and 
hepatic stem cells highlighted the importance of CSCs in 
the progression of the disease [15]. We and others have 
identified important functionally defined liver CSC subsets 
that is marked phenotypically by CD133 and aldehyde 
dehydrogenase (ALDH) activity [16–20]. Liver CSC 
subsets that are positive for CD133 and ALDH possess 
preferential abilities to self-renew, differentiate, initiate 
tumors and resist chemotherapy [16–17, 20–22]. CD133+ 
cells also have prognostic value in HCC and play an 
important functional role in regulating tumorigenesis. 
Despite our growing understanding of the importance 
and existence of such liver CSC subpopulations, the 
mechanism by which these cells are activated in HCC 
remains elusive. Two recent studies have found that 
full-length HBx can induce stem cell-like and CSC-like 
signatures in HCC in human [23] and mouse models [24]. 
However, the role of HBx-ΔC in induction of “stemness” 
phenotypic properties and induction of liver CSC subsets 
has not been explored.
In this study, we tested the hypothesis that the 
frequent carboxyl-terminal truncated from of HBx 
contributes to hepatocarcinogenesis through the induction 
of cancer and stem cell-like properties. Specifically, 
HBxΔC14 and HBxΔC35 were chosen for studies because 
these C-terminal truncated HBx variants have previously 
been shown to abrogate the growth suppressive effects 
induced by full-length HBx, and as a result, can effectively 
promote cell transformation and enhance the proliferative 
activity of neoplastic cells [8, 11, 25]. More importantly, 
they have been identified as natural deletion mutants in 
HCC tissues [8, 11, 25]. We found these two HBx-∆C 
mutants to promote the appearance of a CD133 liver 
cancer stem cell subset and confer cancer and stem cell-
like properties in HCC cell line models. HBx-∆C was 
exclusively detected in HCC cell lines that were raised 
from patients presented with a HBV background with 
concomitant CD133 expression (Hep3B, PLC8024, 
SNU182 and SNU475). The stable overexpression 
of HBx-∆14 or HBx-∆35 in HCC cell line Huh7 and 
immortalized normal liver cell line MIHA resulted in a 
significant increase of the cells ability to self-renew, resist 
5-fluorouracil and sorafenib, migrate and induce capillary 
tube formation in endothelial cells. Overexpression of 
the two naturally occurring C-terminal truncated mutants 
in MIHA cells also resulted in an increase in the CD133 
subset, mediated by STAT3 activation. RNA sequencing 
profiling of MIHA cells with or without HBx-∆C stably 
overexpressed, combined with subsequent rescue 
experiments using a specific FXR inhibitor, identified 
altered FXR activation in C-terminal truncated HBx to 
play a critical role in conferring cancer and stemness 
properties in vitro.
results
Presence of HbV genome in Hcc is associated 
with increased stemness properties
HepG2.2.15 cells are derived from the human 
hepatoblastoma cell line HepG2 and are characterized 
by having stable HBV expression and replication in the 
culture system [26]. As compared to parental HepG2 
cells, we found HepG2.2.15 cells to preferentially 
express stemness associated genes including NANOG, 
SMO, ABCB1, ABCC2, aldehyde dehydrogenase 1A1 
(ALDH1A1) as well as the functional liver CSC marker 
CD133, as detected by qRT-PCR (Figure 1A). Enhanced 
expression of CD133 (0.19% to 75.9%) and ALDH 
activity (8.87% to 83.3%) in HepG2.2.15 was further 
confirmed by flow cytometry analyses (Figure 1A–1B). 
In addition, HepG2.2.15 also displayed an enhanced 
ability to form hepatospheres in vitro, suggesting the 
presence of self-renewing cells (Figure 1D). This suggests 
that the presence of an HBV genome is associated with 
stemness properties in HCC.
c-terminal truncated Hbx is correlated with 
cd133 expression in Hcc cell lines
Previous work by us and others have found 
both full-length and C-terminal truncated HBx to play 
critical pro-oncogenic and pro-metastatic roles in 
hepatocarcinogenesis [10–14, 27–29]. Two recent studies 
have also found full-length HBx to induce stem cell-
like and CSC-like signatures in HCC [23–24]. We set 
out to examine the correlation between the expression 
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of full-length, C-terminal truncated HBx and the well-
document functional liver CSC marker CD133 in a panel 
of immortalized normal liver (MIHA and LO2) and HCC 
cell lines (QSG7701, BEL7402, H2P, H2M, PLC8024, 
Hep3B, Huh7, HepG2, SNU182 and SNU475) in the 
absence or presence of HBV background by qRT-PCR 
and flow cytometry. Specifically, for PCR amplification 
of HBx, sets of PCR primers (44F and XR1 or 44F and 
465R) were used for full-length and C-terminal truncated 
HBx, respectively (Figure 1E). Clones that can only be 
amplified by the primers for the smaller fragment (44F and 
XR1; flanking 197nt), but not for the full-length fragment 
(44F and 465R; flanking 465nt), was considered positive 
for C-terminal truncated HBx (HBx-ΔC). Of the cell 
lines that expressed some degree of CD133 expression, 
PLC8024 has previously been shown to contain multiple 
copies of the integrated HBV genome [30] while Hep3B 
contains only a single copy of integrated HBV genome 
[31]. Huh7 and HepG2 cells were obtained from patients 
with no history of HBV infection [32]; while both 
SNU182 and SNU475 are known to have HBV integration 
in their genome [33]. H2P and H2M were derived from a 
HCC patient that was negative from serologic HBV [34]. 
A positive correlation between C-terminal truncated HBx 
and CD133 expression was observed across this panel of 
cell lines. HCC cell lines that contain HBV integration in 
their genome (PLC8024, Hep3B, SNU182 and SNU475) 
and express CD133 were also found to contain the 
C-terminal truncated HBx DNA fragment. HCC cell lines 
that were raised from patients without HBV infection, 
but express CD133 (H2P, H2M, Huh7 and HepG2), were 
not found to contain the C-terminal truncated HBx DNA 
fragment. Immortalized normal liver cell lines (MIHA 
and LO2) and other HCC cell lines that were raised from 
patients without HBV infection and do not express CD133 
(QSGY7701, BEL7402) were also absent for C-terminal 
truncated HBx (Figure 1F). Conversely, full-length HBx 
was only detected in PLC8024 and did not correlate with 
CD133 expression in HCC (Figure 1F).
c-terminal truncated Hbx overexpression 
induced cancer and stem cell-like properties  
in Hcc cell lines
In view of the close association between C-terminal 
truncated HBx and CD133, we then chose to focus our 
phenotypic characteristics of HBx-associated “stemness” 
in the C-terminal truncated mutants only. Stable 
overexpression of HBxΔC14 and HBxΔC35 was established 
in HBV negative, CD133 absent MIHA cells and HBV 
negative, CD133 positive Huh7 cells. RT-PCR and Western 
Blot analyses were performed to validate overexpression of 
the two C-terminal truncated HBx variants at the genomic 
and proteomic levels, respectively (Figure 2A). 
To delineate the functional relevance of the 
observed positive correlation between natural C-terminal 
truncated HBx and CD133 in HCC cell lines, we 
performed various in vitro assays to examine the ability 
of C-terminal truncated HBx to modify cancer and stem 
cell properties, including their abilities to form spheres 
and serially passage in 3D culture systems (clonogenic 
potential), to resist chemotherapy and targeted therapy 
treatment, as well as to promote cell migration and 
capillary tube formation in endothelial cells. Stable 
overexpression of HBxΔC14 and HBxΔC35 in both 
MIHA and Huh7 led to an enhanced ability of the cells 
to form bigger and more hepatospheres in both primary 
and secondary passages in a significantly shorter period 
of time, than as compared to EV controls (Figure 2B). 
HCC cells with HBxΔC14 and HBxΔC35 stably 
overexpressed were also less sensitive to chemotherapy 
5-fluorouracil and targeted therapy sorafenib, as evident 
by the significant decrease in apoptotic / necrotic 
cells. 5-fluorouracil and sorafenib induced apoptosis 
in MIHA cells decreased from 27.2% to 17.6% and 
10.5% and 20.7% to 11.3% and 11.3%, respectively. 
Similar phenomenon was also observed in Huh7 cells 
where percentage of dead cells following the two 
treatment regimens decreased from 26.2% to 18.5% 
and 20.3% and 66.8% to 39.1% and 29.2%, respectively 
(Figure 2C). Further, stable overexpression of HBxΔC14 
and HBxΔC35 also led to a significant increase in the 
ability of HCC cells to migrate (Figure 2D). Human 
umbilical vein endothelial cells (HUVEC) treated 
with conditioned media collected from HBxΔC14 
and HBxΔC35 overexpressed HCC cells showed an 
enhanced ability to induce capillary tube formation as 
compared with medium collected from EV control cells 
(Figure 2E). Following stable overexpression of the two 
truncated HBx variants in CD133 absent/low MIHA 
cells, expression of CD133 also increased by over 2 to 
3 folds, from 1.96% (EV) to 5.29% (HBxΔC14) and 
4.75% (HBxΔC35). (Figure 2F). Note that since CD133 
expression is already expressed at very high levels in 
Huh7, CD133 expression was not found to be altered 
following truncated HBx variants overexpression (data 
not shown). A recent publication by our collaborator 
Won et al. found STAT3 to promote CD133 transcription 
[35]. Consistent with this, we also found enhanced 
CD133 expression in the two HBx variants to also 
concomitantly express elevated p-STAT3 in MIHA cells, 
suggestive that p-STAT3 represents the mediator or 
initial target molecule for CD133 transcription activation 
(Figure 2G). In addition, a marked up-regulation 
of SOX2 expression was also observed following 
overexpression of the two C-terminal truncated mutants 
in MIHA cells (Figure 2H).
Oncotarget24008www.impactjournals.com/oncotarget
Transcriptome sequencing profiling identifies 
unique gene signatures and functional network 
relating to farnesoid X receptor (FXr) to 
be preferentially deregulated in c-terminal 
truncated Hbx driven Hcc
In an attempt to characterize the molecular 
mechanisms by which C-terminal truncated HBx mutants 
mediate cancer properties, self-renewal and resistance to 
therapy, RNA-Seq profiling was employed to compare 
gene expression profiles between control and C-terminal 
truncated HBx mutants isolated from MIHA cells. 
Following filtering, ~97% of the reads were used for 
downstream analysis. Of this, ~76% of the reads mapped 
to the human transcriptome reference (hg19). Expression 
levels were tabulated in accordance with the number of 
transcripts per million (TPM). At a 1.5-fold cut-off with a 
FDR ≤ 0.05, a total of 995 genes were found de-regulated, 
of which 167 genes were found commonly differentially 
expressed between the two C-terminal truncated HBx 
variants (63 up-regulated and 104 down-regulated) 
(Figure 3A). A visualization of the differential expression 
pattern for these 167 genes is shown in Figure 3B using 
a hierarchical clustering heat map (Figure 3B). To study 
biological functions, Gene Ontology (GO) analysis was 
performed on the de-regulated genes with FDR ≤ 0.05. 
Figure 1: (A) Relative expression of stemness associated genes in HepG2 and HepG2.2.15 HCC cells. (b) Flow cytometry 
dot plot analysis for CD133 expression in HepG2 and HepG2.2.15 HCC cells. (c) Flow cytometry analysis for ALDH activity using the 
ALDEFLUOR kit in HepG2 and HepG2.2.15 cells. DEAB stands for negative control when cells were treated with an ALDH inhibitor, 
diethylaminobenzaldehyde. (d) Representative image and quantification of hepatospheres generated from HepG2 and HepG2.2.15 HCC 
cells. Scale bar = 100 μm. ***p < 0.001. (e) Detection of full-length and C-terminal truncated HBx by RT-PCR using two sets of primers. 
44F and XR1 flanks 197 nucleotides. 44F and 465R flanks 465 nucleotides. (F) RT-PCR analysis of full-length and C-terminal truncated 
HBx in a panel of immortalized normal and HCC cell lines. 18S was amplified as an internal control. CD133 expression was determined 
by flow cytometry analysis.
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A selection of the significant GO terms for biological 
and toxicity functions is shown in Figure 3C (p ≤ 0.05 
and –log (p value) ≥ 1.3), with most of the terms closely 
relating to cancer and in particular, liver cancer and 
hepatocellular carcinoma (Figure 3C). The same gene 
set was also surveyed using the pathway analysis tool 
by Ingenuity Pathway Analysis (IPA) where FXR/RXR 
activation (Figure 4A–4C) (p ≤ 0.05 and –log (p value) 
≥ 1.3) and interactions between drug metabolism related 
genes (Figure 4B) were found well represented in the 
de-regulated gene set (Figure 4A to 4C). FXR/RXR 
pathway activation and drug metabolism related genes 
have previously been shown to play critical roles in 
mediating chemoresistance, and in particular liver tumor 
chemoresistance against genotoxic compounds [36–38]. 
To validate our profiling results, qRT-PCR was performed 
to validate 27 selected commonly deregulated mRNAs 
involved in FXR/RXR activation and drug metabolism, 
Figure 2: (A) Validation of HBx-∆14 and HBx-∆35 (expressing 14- and 35-amino acid C-terminal truncation) overexpression 
into HBV negative, CD133 absent MIHA cells and HBV negative, CD133 present Huh7 cells at genomic levels by RT-PCR 
and proteomic levels by Western blot. Empty vector (EV) transfected as control. 18S and beta-actin as internal controls for RT-PCR 
and Western blot, respectively. (b) Representative image and quantification of hepatospheres (primary and secondary passages) in MIHA or 
Huh7 cells with HBx-∆14 and HBx- ∆35 stably overexpressed. Scale bar = 100 μm. ***p < 0.001, **p < 0.01, *p < 0.05. (c) Percentage 
of Annexin V positive cells in MIHA or Huh7 cells with HBx-∆14 and HBx-∆35 stably overexpressed, following 5-fluorouracil (5-FU) 
or sorafenib treatment. (d) Representative image and quantification of number of cells that migrated in MIHA or Huh7 cells with HBx-
∆14 and HBx-∆35 stably overexpressed. Scale bar = 100 μm. ***p < 0.001, **p < 0.01. (e) Representative image and quantification of 
capillary tubes formed by HUVECs following treatment with supernatant collected from MIHA or Huh7 cells with HBx-∆14 and HBx-
∆35 stably overexpressed. Scale bar = 100 μm. *p < 0.05. (F) Flow cytometry dot plot analysis for CD133 expression in MIHA cells with 
HBx-∆14 and HBx-∆35 stably overexpressed. (G) Western blot analysis of MIHA with EV, HBx-∆14 or HBx- ∆35 stably overexpressed 
for phosphorylated and total STAT3 expression. (H) Relative expression of SOX2 in MIHA cells with or without HBx-∆14 and HBx- ∆35 
stably overexpressed.
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including LIPC, VLDLR, FGA, CETP, APOA4, SLC51A/
OSTA, GSTM2, UGT2B4, HPX, C4B, AGT, APOC3, 
ABCB4, SAA4, APOA1, PKLR, FETUB, UGT1A1, 
ABCB1, DPYD, SLCO1B3, UGT2B11, PPARG, 
IL18, ABCG2, PGC1A, CREBBP/CBP, of which over 
half could be confirmed in both C-terminal truncated 
mutants (Figure 4E, highlighted in red), suggesting that 
C-terminal truncated HBx mutants confer resistance 
to standard therapy via activation of these predicted 
pathways. To further confirm the involvement of 
FXR pathway activation, a selective FXR inhibitor 
(Z-guggulsterone) was used as a rescue in several in vitro 
functional studies. Addition of Z-guggulsterone (25 µM) 
in C-terminal truncated HBx mutants attenuated the 
abilities of the cells to form hepatospheres (Figure 5A) 
and migrate (Figure 5B), suggesting that FXR activation 
in C-terminal truncated HBx mutants is critical in 
conferring cancer and stemness properties to these cells. 
Note that rescue experiments were also carried out using 
a selective RXR inhibitor (UVI 3003). However, its 
addition did not result in a rescued functional phenotype 
(data not shown).
dIscussIon
Chronic hepatitis B virus (HBV) infection is a 
major risk factor for HCC. There is mounting evidence 
to support a role for the hepatitis B virus X (HBx) gene 
and protein in the pathogenesis of HBV-induced HCC. 
HBx gene is often included, and remains functionally 
active, in the HBV DNA that is frequently integrated into 
cellular DNA during hepatocellular carcinogenesis. HBx 
protein has now been extensively shown to promote tumor 
growth and resistance to therapy in human HCC through 
modulating apoptosis, telomerase activity, nucleotide 
excision repair, cell cycle, cell adhesion, epigenetics, 
etc. More recent studies have also found HBx to induce 
tumorigenicity of hepatic progenitor cells in DDC-treated 
HBx transgenic mice [24], to inhibit cell differentiation in 
hepatic progenitor cells [39] and to play an anti-apoptosis 
role in hepatic progenitor cells by activating the Wnt/
beta-catenin pathway [40]. HBx has also been shown to 
trigger HCC transformation by promoting properties that 
are characteristics of CSCs and EpCAM [41–42]. Our 
results is consistent with these reports where the presence 
of a stable and replicating HBV genome in the HepG2 
culture system (HepG2.2.15) resulted in the enhanced 
ability of the cells to self-renew as demonstrated by 
spheroid formation assay and the induced expression of 
stemness related genes and markers (ABCB1, ABCC2, 
ALDH1A1, CD133, NANOG and SMO) at both genomic 
and proteomic levels.
Our group and others have previously reported that 
HBV integration is detected in 80–90% of host genomes 
from HBV-infected HCC cases and that the HBx gene 
is often partially deleted during the integration process, 
causing the C-terminal truncation of HBx [6–8]. We 
and others have also found C-terminal truncated HBx 
to play a critical pro-oncogenic and pro-metastatic role 
in hepatocarcinogenesis [10–14] through modulating 
GAS2 mediated deregulation of cell cycle and senescence, 
c-Jun/MMP10 and distinct miRNA transcription. 
Figure 3: (A) Venn diagram of differentially regulated genes based on gene fold change ≥ 1.5 and FDR ≤ 0.05 between EV 
vs. HBx-∆14 and EV vs. HBx-∆35 in MIHA cells. Genes that were significantly and commonly deregulated are shown in the overlapping 
area. (b) Unique gene signatures of MIHA cells with or without expression of HBx-∆14 and HBx-∆35, as shown by hierarchical cluster 
analysis (fold change ≥ 1.5 and FDR ≤ 0.05). Each cell in the matrix represents a particular expression level, where red and green cells 
indicate high and low gene expression, respectively. (c) Functional analysis of C-terminal truncated HBx mutants regulated genes by IPA. 
The p value was calculated using Fisher exact test to show the likelihood of association between our dataset of deregulated genes and a 
biological or toxicological function.
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However, whether C-terminal truncated HBx trigger 
HCC formation through induction of cancer stem cell-like 
features or a CSC subpopulation remains unknown. 
Here in this study, we attempted to explore the role 
of C-terminal truncated HBx in induction of “stemness” 
phenotypic properties and induction of a CD133 subset. We 
chose the previously widely reported C-terminal truncated 
HBx mutants with a breakpoint at 140 aa (HBxΔC14) 
and breakpoint at 119 aa (HBxΔC35) for our cell model 
because these two mutants have been shown to abrogate 
the growth suppressive effects induced by full-length HBx, 
effectively promoting cell transformation and enhancing 
the proliferative activity of neoplastic cells [8, 11, 25, 29]. 
These two mutants were also selected because they have 
previously been identified as natural deleting mutants 
in HCC tissues [8, 25]. HBx-∆C was exclusively 
detected in HCC cell lines that were raised from patients 
presented with a HBV background and with concomitant 
CD133 expression (Hep3B, PLC8024, SNU182 and 
SNU475). Both HBxΔC14 and HBxΔC35 also induced 
Figure 4: (A) Pathway analysis of C-terminal truncated HBx mutants regulated genes by IPA. The p value was calculated using 
Fisher exact test to show the likelihood of association between our dataset of deregulated genes and canonical pathways. (b) FXR/RXR 
interaction and functional network identified by IPA. Genes in red and green indicate up- and down-regulated genes found in C-terminal 
truncated HBx mutants, respectively. Genes in white are not included in our dataset, but added by IPA to complete the network connections. 
Molecules predicted to be activated and inhibited by the IPA molecule activity predictor are labeled in orange and blue, respectively. 
(c) Heatmap showing fold change of individual genes involved in FXR/RXR pathway and drug metabolism. A total of 22 and 5 genes were 
found commonly up- and down-regulated, respectively.  Each cell in the matrix represents a particular expression level of genes, where 
red and green cells indicate high and low gene expression, respectively. (d) Drug metabolism interaction and functional network identified 
by IPA. Genes in red and green indicate up- and down-regulated genes found in C-terminal truncated HBx mutants, respectively. Genes in 
pink are related to drug metabolism. Genes in white are not included in our dataset, but added by IPA to complete the network connections. 
Molecules predicted to be activated and inhibited by the IPA molecule activity predictor are labeled in orange and blue, respectively. 
(e) qRT-PCR validation of identified differentially expressed genes relating to FXR/RXR pathway and drug metabolism in MIHA cells 
with or without HBx-∆14 and HBx-∆35 stably overexpressed. 
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the appearance of a CD133 liver CSC subpopulation in 
MIHA cells, mediated via STAT3 activation. CD133 is 
a well-documented functional liver CSC marker, known 
to be present in HCC tumors and contribute to tumor 
recurrence and therapy resistance [16–22]. Recent study 
by Won et al. found CD133 transcription in HCC to be 
mediated via IL-6/STAT3 activation [35]. Interestingly, 
full-length HBx was previously found to induce EpCAM 
expression in HCC [23, 42], whose expression is known 
to overlap to some degree with CD133 [22]. We then 
went on to test the ability of MIHA and Huh7 cells stably 
overexpressed with empty vector control, HBxΔC14 and 
HBxΔC35 to confer various cancer and stem cell-like 
properties in vitro. As compared to the control, HBx-
∆14 or HBx-∆35 resulted in a significant increase of the 
cells ability to self-renew, resist chemotherapy (5-FU) 
and the only targeted therapy approved for treatment 
of HCC (sorafenib), migrate and induce tube formation 
in endothelial cells. Thus, HBxΔC14 and HBxΔC35 
showed more pronounced phenotypes consistent with 
stem cell behavior than EV control cells. Hence, these 
phenotypic characteristics presented were consistent with 
the induction of CD133 marker by C-terminal truncated 
HBx mutants.
To further dissect the mechanistic basis of the 
HBxΔC14 and HBxΔC35 mediated stemness, a global 
transcriptome sequencing profiling was employed to 
examine the altered profiles of C-terminal truncated 
mutants. HBxΔC14 and HBxΔC35 exhibit an enhanced 
expression of stemness gene signatures involved in 
FXR/RXR activation and drug metabolism, including 
ABC transporters (ABCG2, ABCB1 and ABCB4), 
solute carrier family members (SLCO1B3 and SLC51A/
OSTA), cytosolic glycosyltransferase (UGT1A1, 
UGT2B11 and UGT2B4), homeostasis-related genes 
(LIPC, VLDLR, PPARG, PGC1A, HPX), apolipoproteins 
(APOC3, APOA4 and APOA1), as well as FGA, CETP, 
GSTM2, C4B, AGT, SAA4, PKLR, FETUB, IL18, 
DPYD and CREBBP/CBP. This is consistent with 
past studies where activation of the nuclear receptor 
FXR enhances hepatocyte chemoprotection and liver 
tumor chemoresistance against genotoxic compounds 
[37–38]; and the link between ABCG2 and resistance 
to chemotherapy in HCC [43]. Subsequent rescue 
experiments with a selective FXR inhibitor further 
validated this bioinformatics prediction, suggesting 
that C-terminal truncated HBx can mediate cancer and 
stemness features via FXR activation. 
Figure 5: (A) Representative image and quantification of hepatospheres in MIHA cells with HBx-∆14 and HBx- ∆35 stably overexpressed, 
in the absence or presence of FXR inhibitor, Z-guggulsterone (Z-gugg; 25 µM). Scale bar = 100 μm. *compared to EV with ***p < 0.001, 
**p < 0.01, *p < 0.05. #compared to DMSO with ##p < 0.01, #p < 0.05. (b) Representative image and quantification of number of cells that 
migrated in MIHA cells with HBx-∆14 and HBx-∆35 stably overexpressed in the absence or presence of FXR inhibitor, Z-guggulsterone 
(Z-gugg; 25 µM). Scale bar = 100 μm. *compared to EV with ***p < 0.001, *p < 0.05. #compared to DMSO with ###p < 0.001, #p < 0.05. 
(c) Cartoon summary of the role of C-terminal truncated HBx variants, in particular HBx-∆14 and HBx-∆35, in promoting cancer and stem 
cell-like features in vitro in HCC.
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To conclude, our data suggest that C-terminal 
truncated HBx, in particular at 140 aa and 119 aa 
breakpoints, enhances stemness properties in vitro and 
induces a CD133 liver CSC subpopulation in HCC through 
modulating a distinct altered genomic profile involving 
FXR pathway and possibly drug metabolism (Figure 5C). 
MAterIAls And MetHods
reagents
Sorafenib was purchased from LC Laboratories. 
FXR inhibitor, Z-guggulsterone was purchased from 
Tocris Bioscience and used at 25 µM.
cell lines
Human HCC cell lines Hep3B, SNU-182, SNU-
475 and HepG2, were purchased from American Type 
Culture Collect (ATCC). Human liver cell line LO2 and 
HCC cell lines PLC8024, QSG-7701 and BEL7402, were 
obtained from the Institute of Virology, Chinese Academy 
of Medical Sciences, Beijing, China. HCC cell line, 
Huh7, was provided by Dr. H. Nakabayashi, Hokkaido 
University School of Medicine, Japan. H2P and H2M were 
previously established in our laboratory [34]. Immortalized 
normal liver cell line, MIHA, was provided by Dr. J. R. 
Chowdhury, Albert Einstein College of Medicine, New 
York. Human umbilical vein endothelial cells (HUVEC) 
were purchased from Invitrogen. HepG2.2.15 cells were 
cultured in DMEM supplemented with 10% fetal calf 
serum, 2 mM L-glutamine and 380 µg/mL G418. All 
cell lines used in this study were regularly authenticated 
by morphological observation and tested for absence of 
Mycoplasma contamination (MycoAlert, Lonza). 
Flow cytometry and cell sorting
Flow cytometry analysis or flow cytometry cell 
sorting was conducted using PE-conjugated mouse anti-
human CD133 (Miltenyi Biotec) or its respective isotype 
control. ALDEFLUOR reagent (Stem Cell Technologies) 
was used for the immunofluorescent detection of 
intracellular ALDH enzyme activity. Samples were 
analyzed on BD FACSCanto II (BD Biosciences) with 
data analyzed by FlowJo (Tree Star Inc.). 
detection of full-length and c-terminal 
truncated Hbx by rt-Pcr
RT-PCR was performed in matched non-tumor and 
HCC tissue samples using primers encompassing the entire 
and different lengths of X gene, as previously described 
[10]. Specifically, for PCR amplification of HBx, sets of 
PCR primers (44F: 5ʹ-TCCTTTGTTTACGTCCCGTC-3ʹ, 
XR1: 5ʹ-GCAGATGAGAAGGCACAGAC-3ʹ and 465R: 
5ʹ-TTAGGCAGAGGTGAAAAAGTTGC-3ʹ) were used 
for full-length and C-terminal truncated HBx, respectively. 
Clones that can only be amplified by the primers for the 
smaller fragment (flanking 197nt), but not for the full-
length fragment (flanking 465nt), was considered positive 
for C-terminal truncated HBx. RT-PCR products were 
analyzed by electrophoresis on a 1.5% agarose gel, stained 
with ethidium bromide and visualized on a Gel Doc XR 
System (Bio-Rad).
Quantitative real-time Pcr
Total RNA was extracted using RNA-IsoPlus 
(Takara) and cDNA was synthesized by PrimeScript RT 
Master Mix (Takara). qRT-PCR was performed with 
SYBR Green PCR Master Mix (Applied Biosystems) 
and primers as listed in Supplementary Table 1 on an ABI 
Prism 7900 System with data analyzed using the ABI SDS 
v2.3 software (Applied Biosystems). Relative expression 
differences were calculated using the 2-ΔΔCt method. 
Western blot
Protein lysates were quantified and resolved on 
a SDS-PAGE gel, transferred onto a PVDF membrane 
(Millipore) and immunoblotted with a primary antibody, 
followed by incubation with a secondary antibody. 
Antibody signal was detected using an enhanced 
chemiluminescence system (GE Healthcare). The following 
antibodies were used: FLAG (M2) (1:2000, Sigma-Aldrich, 
F3165), p-STAT3 (1:1000, Cell Signaling, 9145S), total 
STAT3 (1:1000, Cell Signaling, 9132) and β-actin (1:5000, 
Sigma-Aldrich, A5316). 
establishment of c-terminal truncated Hbx 
stably expressing cell lines
Viral DNA samples extracted from the sear of 
HCC patient CH230 were used for the amplification 
and cloning of HBx gene as previously described [11]. 
HBx fragments from patient CH230 were amplified by 
PCR using a forward primer carrying Kozak and flag-
tag sequence and reverse primers with an artificial stop 
codon at different deletion sites. PCR products were 
cloned into the HindIII and EcoR1 restriction sites of a 
pcDNA6b vector to generate flag-tagged HBxΔ14 and 
HBxΔ35, expressing 14- and 35- aa carboxyl-terminal 
truncation, respectively. Huh7 and MIHA cells were 
transfected using Lipofectamine 2000 (Invitrogen) with 
stable expressing pooled clones selected using blasticidin 
at a concentration of 5 µg/mL. Empty vector pcDNA6b-
3xFLAG was also transfected into Huh7 and MIHA cells 
as negative controls.
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Hepatosphere-forming and self-renewal assay
Single cells were cultured in 300 µl of serum-free 
DMEM/F12 medium (Invitrogen) supplemented with 
20 ng/ml human recombinant epidermal growth factor 
(Sigma-Aldrich), 10 ng/ml human recombinant basic 
fibroblast growth factor (Sigma-Aldrich), 4 µg/ml insulin 
(Sigma-Aldrich), B27 (1:50; Invitrogen), 500 U/ml 
penicillin, 500 µg/ml streptomycin (Invitrogen) and 1% 
methylcellulose (Sigma-Aldrich). Cells were cultured in 
suspension in poly-HEMA-coated 24-well plates. Cells 
were replenished with 30 µl of supplemented medium 
every second day. To propagate spheres in vitro, spheres 
were collected by gentle centrifugation and dissociated to 
single cells using TrypLE Express (Invitrogen). Following 
dissociation, trypsin inhibitor (Invitrogen) was used to 
neutralize the reaction, and the cells were cultured to 
generate the next generation of spheres.
cell motility assay
Migration assays were conducted in 24-well 
Millicell hanging inserts (Millipore). Cells re-suspended 
in serum free DMEM were added to the top chamber 
and medium supplemented with 10% FBS was added to 
the bottom chamber as a chemoattractant. After 48 hrs 
of incubation at 37°C, cells that migrated through the 
membrane were fixed and stained with crystal violet 
(Sigma-Aldrich). The number of cells was counted in 
3 random fields under 20x objective lens and imaged using 
SPOT imaging software (Nikon).
Annexin V apoptosis assay
Cells were treated with 5-FU (Huh7 with 300 µg/mL 
and MIHA with 25 µg/mL) or sorafenib (Huh7 with 5 µM 
and MIHA with 2 µM) for 48 hrs. Following treatment, 
cells were harvested and stained with propidium iodide 
(PI) and FITC-conjugated Annexin V as provided by the 
Annexin V-FLUOS Staining Kit (Roche). Samples were 
analyzed on BD FACSCanto II (BD Biosciences) with 
data analyzed by FlowJo (Tree Star Inc.).
capillary tube formation assay in HuVecs
Cells were cultured in 6-well plates in complete 
medium, with culture medium replaced with serum free 
medium after 24 hrs. Conditioned medium was collected 
and filtered after incubation for a further 24 hrs. HUVECs 
were co-cultured with conditioned medium for 24 hrs. 
Capillary tube formation assays were then conducted 
on BD Matrigel Basement Membrane Matrix (BD 
Biosciences). The number of capillary tubes formed was 
counted in 3 random fields under a 20x objective lens and 
imaged using SPOT imaging software. Specifically, the 
formation of 1 capillary tube was defined as a connection 
between 2 cells. 
rnA sequencing, pre-processing, alignment and 
expression quantification
RNA-Seq was performed as a service at the Centre 
for Genomic Sciences of The University of Hong Kong 
using the Illumina HiSeq platform. cDNA libraries were 
prepared using the KAPA Stranded mRNA-Seq Kit using 
1 µg of total RNA. HiSeq PE Cluster Kit v4 with cbot was 
used for cluster generation on the flow cell. Illumina HiSeq 
SBS Kit v4 was used for pair-end 101bp sequencing. To 
obtain high quality reads for downstream analysis, raw 
sequencing reads were first filtered for adapter sequences 
and low quality (reads containing unknown bases and 
bases having a quality value of ≤ 10) and removed using 
cutadapt [44] and custom scripts bases. Low complexity 
bases (more than 10bp of continuous bases of “A” and 
“T”) were trimmed from the 3’ end using prinseq [45]. 
Reads with length < 40bp were then discarded. Sequencing 
reads were also filtered for rRNA sequence and 
remaining high quality reads were used for downstream 
analysis. High quality reads were aligned against human 
transcriptome (hg19) using RSEM package v1.2.21 [46]. 
Expression estimation and tests for differential expression 
were performed using EBSeq v1.6.0 in the RSEM package 
[47]. Transcriptome sequencing data available publicly at 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE71993.
Pathway analysis
RNA sequencing data were formatted and uploaded to 
the IPA software (Ingenuity Systems). Filter parameters (fold 
change ≥ 1.5 with FDR ≤ 0.05) for deregulated genes were 
set before running analysis. Top 10 results for core analysis 
on biological and toxicological functions, and canonical 
pathways were sorted according to the p-value. Fisher’s 
exact test was used to estimate the probability of association 
between a set of molecules and a function or pathway. The 
pathway/network shows the molecular relationship between 
molecules based on Ingenuity Knowledge Database.
statistical analysis
Statistical analyses were performed using GraphPad 
Prism 5.0 (GraphPad Software, Inc.) and SPSS version 
21.0 (IBM). Independent Student’s t-test was used 
to compare the mean value of two groups. Error bars 
represent SD values. Statistical significance was defined 
as p ≤ 0.05.
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